EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment

Sammy M Njenga iD, Henry Kanyi, Collins Okoyo, Edward Githinji, Cassian Mwatele, Sultani H Matendechero, Wyckliff P Omondi, Patrick N Gitahi, Chrispin Owaga, Joyce K Onsongo, Katherine Gass

PLOS Neglected Tropical Diseases · 2024

DOI: 10.1371/journal.pntd.0011942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Sammy M Njenga und 10 weiteren Autor:innen. Beteiligte Einrichtung: Eastern and Southern Africa Centre of International Parasite Control, Kenya Medical Research Institute, Nairobi, Kenya. Hauptthemen laut MEDLINE: Elephantiasis, Filarial, Albendazole, Diethylcarbamazine, Ivermectin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Bill and Melinda Gates Foundation, Coalition for Operational Research on Neglected Tropical Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The World Health Organization (WHO) endorsed the use of triple-drug mass drug administration (MDA) regimen with ivermectin, diethylcarbamazine (DEC) and albendazole (commonly abbreviated as IDA) to accelerate the elimination of lymphatic filariasis (LF) as a public health problem in settings where onchocerciasis is not co-endemic. The National Programme for Elimination of LF (NPELF) in Kenya was among the first adopters of the IDA-MDA and two annual rounds were provided in 2018 and 2019 to the residents of Lamu County and Jomvu sub-County in the coast region. This study documented the feasibility of successfully delivering the two rounds of IDA-MDA. An operational research study was undertaken to determine efficient sampling strategies, indicators, and the appropriate population groups that could be used for the monitoring and evaluation of LF programs using IDA-MDA for the elimination of the disease as a public health problem. Two cross-sectional surveys were conducted at baseline in 2018 before IDA-MDA and an impact assessment 17 months after the second round of IDA-MDA. The reported epidemiological treatment coverage was at least 80% in all implementation units during each round of IDA-MDA. Blood samples were tested for filarial antigenemia using commercial Filariasis Test Strips (FTS) and any individual found to be positive was tested again at night for the presence of microfilariae in finger prick blood smears using microscopy. The overall prevalence of circulating filarial antigen (CFA) was relatively low at the baseline survey with Jomvu having 1.39% (95% CI: 0.91, 2.11) and Lamu having 0.48% (95% CI: 0.21, 1.13). Significant reduction in CFA prevalence was observed during the impact assessment after the two annual rounds of mass treatment. The overall relative reduction (%) in CFA prevalence following the two rounds of MDA with IDA was significant in both Jomvu (52.45%, Z = -2.46, P < 0.02) and Lamu (52.71%, Z = -1.97, P < 0.05). Heterogeneity, however, was observed in the CFA prevalence reduction between random and purposive clusters, as well as between adult and child populations. The results of the impact assessment survey offered strong evidence that it was safe to stop the IDA-MDA in the two EUs because transmission appears to have been interrupted. It is also important to implement a post-treatment surveillance system which would enable efficient detection of any recrudescence of LF transmission at a sub-evaluation unit level. Our findings show that IDA-MDA may be considered for acceleration of LF elimination in other settings where onchocerciasis is not co-endemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Elephantiasis, FilarialAlbendazoleDiethylcarbamazineIvermectinMass Drug AdministrationFilaricidesDrug Therapy, CombinationDisease EradicationHumansKenyaFemaleMaleAdultAdolescentYoung AdultMiddle AgedChildCross-Sectional StudiesAnimalsPrevalenceAgedChild, PreschoolWuchereria bancrofti

Substanzen

AlbendazoleDiethylcarbamazineIvermectinFilaricides

Autor:innen und Institutionen

  • Eastern and Southern Africa Centre of International Parasite Control, Kenya Medical Research Institute, Nairobi, Kenya.
  • Department of Epidemiology, Statistics and Informatics, Kenya Medical Research Institute, Nairobi, Kenya.
  • Vector-Borne and Neglected Tropical Diseases Unit, Ministry of Health, Nairobi, Kenya.
  • Evidence Action, Nairobi, Kenya.
  • WHO Country Office, World Health Organization, Nairobi, Kenya.
  • NTD Support Center, Task Force for Global Health, Atlanta, Georgia, United States of America.

ORCID-Profile: Sammy M Njenga

Förderung

  • World Health Organization
  • Bill and Melinda Gates Foundation
  • Coalition for Operational Research on Neglected Tropical Diseases

Zitieren

APA

Njenga, S. M., Kanyi, H., Okoyo, C., Githinji, E., Mwatele, C., Matendechero, S. H., Omondi, W. P., Gitahi, P. N., Owaga, C., Onsongo, J. K., & Gass, K. (2024). Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011942

Vancouver

Njenga SM, Kanyi H, Okoyo C, Githinji E, Mwatele C, Matendechero SH, et al. Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0011942

BibTeX
@article{Njenga2024,
  author = {Njenga, Sammy M and Kanyi, Henry and Okoyo, Collins and Githinji, Edward and Mwatele, Cassian and Matendechero, Sultani H and Omondi, Wyckliff P and Gitahi, Patrick N and Owaga, Chrispin and Onsongo, Joyce K and Gass, Katherine},
  title = {Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2024},
  doi = {10.1371/journal.pntd.0011942}
}
Kostenlos starten →